Consumer Stocks Climb — Consumer Roundup
The Consumer Discretionary Select Sector SPDR Fund gained 0.5% as investors anticipated the latest U.S. inflation reading alongside generally positive economic updates.
Kimberly-Clark will sell its personal protective equipment business to Ansell for $640 million in cash, agreeing to a deal that the Australian company's chief executive said had been under consideration for years.
Tesla reached a settlement with the family of a driver who died in a 2018 crash involving the company's driver-assistance technology Autopilot, days before attorneys were poised to deliver opening statements in a widely anticipated trial.
Neogen shares tumbled 9.3% following a lower revenue outlook for fiscal 2024.The food-safety and animal-safety products guided for revenue between $910 million and $920 million compared to a prior forecast of $935 million to $955 million.
Write to Patrick Sullivan at patrick.sullivan@wsj.com
(END) Dow Jones Newswires
April 09, 2024 16:59 ET (20:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track